# US 2012/0252854 A1 · Crystalline forms of thiazolidinedione compound and its manufacturing method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252854 A1
- Document ID: US20120252854A1
- Status: Published application
- Kind: A1
- Application number: 13/465,202
- Filed: 2012-05-07
- Published: 2012-10-04
- Earliest claimed: 2007-02-08
- Assignees: Daiichi Sankyo Company, Limited
- Inventors: Hisaki Kajino; Yutaka Ikeuchi; Hiroshi Miyamoto; Eiji Numagami; Satoru Nihei
- Web page: https://patentgrep.com/patent/US20120252854A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A crystalline form of a hydrate of a dihydrochloride 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimidazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by the following formula: wherein the crystalline form shows main peaks at interplanar spacings of 10.42, 5.85, 5.52, 3.84, 3.46 and 2.95 angstroms in X-ray powder diffraction obtained with Cu Kα line radiation (wavelength λ=1.54 angstroms).

## Claims

### Claim 1

A crystalline form of a hydrate of a dihydrochloride of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimidazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by the following formula:
wherein the crystalline form shows main peaks at interplanar spacings of 10.42, 5.85, 5.52, 3.84, 3.46 and 2.95 angstroms in X-ray powder diffraction obtained with Cu Kα line radiation (wavelength λ=1.54 angstroms).

### Claim 2 (depends on 1)

A method of manufacturing the crystalline form according to claim 1, comprising crystallizing a hydrate of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimidazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione dihydrochloride from methanol.

### Claim 3 (depends on 1)

A method of treating or preventing diabetes in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of the crystalline form according to claim 1.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the mammal is a human.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the diabetes is type 2 diabetes.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the method is for treating a human.

### Claim 7 (depends on 1)

A method of treating or preventing a cancer in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of the crystalline form according to claim 1.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the mammal is a human.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the cancer is stomach cancer, colon cancer, lung cancer, breast cancer, pancreatic cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing's sarcoma, liposarcoma, multiple myeloma or leukemia.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the method is for treating a human.

### Claim 11 (depends on 1)

A composition comprising a pharmaceutically effective amount of the crystalline form according to claim 1, in combination with a pharmaceutically acceptable additive.

### Claim 12 (depends on 11)

The composition according to claim 11, wherein the pharmaceutically effective amount is an anti-cancer effective amount.

### Claim 13 (depends on 11)

The composition according to claim 11, wherein the pharmaceutically effective amount is an anti-diabetes effective amount.

### Claim 14

A method of treating or preventing diabetes in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a crystalline form of a hydrate of a dihydrochloride of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimidazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by the following formula:
wherein the crystalline form shows main peaks at interplanar spacings of 7.06, 5.79, 5.43, 4.44, 4.18, 3.97, 3.91, 3.68, 3.61, 3.48, 3.24 and 2.97 angstroms in X-ray powder diffraction obtained with Cu Kα line radiation (wavelength λ=1.54 angstroms).

### Claim 15 (depends on 14)

The method according to claim 14, wherein the mammal is a human.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the diabetes is type 2 diabetes.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the method is for treating a human.

### Claim 18

A method of treating or preventing cancer in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a crystalline form of a hydrate of a dihydrochloride of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimidazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by the following formula:
wherein the crystalline form shows main peaks at interplanar spacings of 7.06, 5.79, 5.43, 4.44, 4.18, 3.97, 3.91, 3.68, 3.61, 3.48, 3.24 and 2.97 angstroms in X-ray powder diffraction obtained with Cu Kα line radiation (wavelength λ=1.54 angstroms).

### Claim 19 (depends on 18)

The method according to claim 18, wherein the mammal is a human.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the cancer is stomach cancer, colon cancer, lung cancer, breast cancer, pancreatic cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing's sarcoma, liposarcoma, multiple myeloma or leukemia.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the method is for treating a human.

### Claim 22

An anti-cancer composition comprising (i) an anti-cancer effective amount of a crystalline form of a hydrate of a dihydrochloride of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimidazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by the following formula:
wherein the crystalline form shows main peaks at interplanar spacings of 7.06, 5.79, 5.43, 4.44, 4.18, 3.97, 3.91, 3.68, 3.61, 3.48, 3.24 and 2.97 angstroms in X-ray powder diffraction obtained with Cu Kα line radiation (wavelength λ=1.54 angstroms) and (ii) a pharmaceutically acceptable additive.
